immunotherapy / TET2 Cancer Research Results

immuno, immunotherapy: Click to Expand ⟱
Features: 
Immunotherapy is not one drug class. It includes:
-Immune checkpoint inhibitors (PD-1, PD-L1, CTLA-4)
-CAR-T therapies
-Monoclonal antibodies
-Cytokine therapies (IL-2, IFN-α)
-Cancer vaccines
-Bispecific T-cell engagers
PD-1 blockade antibody therapy is one of the cornerstone approaches in modern cancer immunotherapy.
Under normal physiological conditions, when PD-1 binds to its ligands (PD-L1 or PD-L2) on other cells, it functions as a "checkpoint" to reduce overly active T cell responses and prevent autoimmunity.
PD-1 blockade therapies involve monoclonal antibodies that target either PD-1 or its ligand PD-L1.
• By blocking the interaction between PD-1 and its ligands, these antibodies effectively release the "brakes" on T cells.
• The re-activated T cells can then recognize and destroy cancer cells more efficiently.

Immunotherapy Class Example Agents Primary Target Core Mechanism Interaction Considerations Net Effect
PD-1 inhibitors Nivolumab, Pembrolizumab PD-1 receptor on T cells Blocks inhibitory PD-1 signaling → restores cytotoxic T-cell activity High-dose steroids or strong immunosuppressants may blunt effect; autoimmune risk ↑ Anti-tumor immune activation
PD-L1 inhibitors Atezolizumab, Durvalumab PD-L1 on tumor/immune cells Prevents PD-L1 from engaging PD-1 → enhances T-cell response Similar immune-related adverse event (irAE) profile as PD-1 inhibitors ↑ Immune activation
CTLA-4 inhibitors Ipilimumab CTLA-4 checkpoint Enhances early T-cell priming in lymph nodes Higher autoimmune toxicity risk vs PD-1 class ↑ T-cell priming
CAR-T therapy CD19 CAR-T products Tumor antigen (e.g., CD19) Genetically engineered T cells directly target tumor cells Risk of cytokine release syndrome (CRS) and neurotoxicity Direct immune-mediated tumor killing
Monoclonal antibodies (non-checkpoint) Trastuzumab, Rituximab Specific tumor antigens Antibody-dependent cellular cytotoxicity (ADCC) or receptor blockade Combination with chemo common; immune activation depends on Fc engagement Targeted immune-mediated killing
Cytokine therapy IL-2, IFN-α Immune activation pathways Stimulates T-cell and NK cell proliferation High systemic toxicity; rarely used now vs checkpoint inhibitors Broad immune stimulation
Cancer vaccines mRNA or peptide-based Tumor antigens Induces tumor-specific immune memory Often combined with checkpoint blockade Adaptive immune priming
Bispecific T-cell engagers Blinatumomab CD3 + tumor antigen Bridges T cells directly to tumor cells CRS risk; continuous infusion in some protocols Direct T-cell redirection


TET2, tet oncogene family member 2: Click to Expand ⟱
Source: CGL-Driver Genes
Type: TSG
TET2 (Ten-Eleven Translocation 2) is a gene that encodes an enzyme involved in the process of DNA demethylation, which is crucial for regulating gene expression and maintaining genomic stability.
TET2 is a critical epigenetic regulator whose dysregulation—mainly through mutations—plays a significant role in the development and progression of various cancers, particularly in hematologic malignancies. Its impact on DNA methylation and subsequent gene expression changes makes it a key player in oncogenesis and a potential target for epigenetic therapies. The prognostic implications of TET2 mutations are context-dependent, contributing valuable information regarding disease progression, patient outcomes, and treatment response.

Loss-of-function mutations or reduced activity of TET2 can lead to aberrant DNA methylation patterns, which may result in inappropriate gene silencing (including of tumor suppressor genes) or activation of oncogenes. This disruption in the normal epigenetic landscape contributes to the development and progression of various cancers, particularly hematological malignancies such as myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML).
Scientific Papers found: Click to Expand⟱
3121- VitC,  immuno,    Ascorbic acid induced TET2 enzyme activation enhances cancer immunotherapy efficacy in renal cell carcinoma
- in-vivo, RCC, A498 - in-vitro, RCC, 786-O
TET2↑, eff↑, eff↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Drug Metabolism & Resistance ⓘ

eff↑, 2,   TET2↑, 1,  
Total Targets: 2

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: TET2, tet oncogene family member 2
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:207  Target#:303  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page